| dc.contributor.author | Hazboun, Nader | |
| dc.date.accessioned | 2019-03-15T10:53:14Z | |
| dc.date.available | 2019-03-15T10:53:14Z | |
| dc.date.issued | 2019-03 | |
| dc.identifier.issn | 2163-2189 | |
| dc.identifier.uri | http://dspace.bethlehem.edu:8080/xmlui/handle/123456789/106 | |
| dc.description.abstract | The expression of immune checkpoint molecules such as programmed cell death ligand 1 (PD-L1) on the
surface of cancer cells and programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) on
the surface of T-cells results in immune tolerance. Despite the unprecedented success of checkpoint inhibitors in cancer
therapy, only a minority of patients respond durably. This review focuses on the role of immune checkpoint blockade in
cancer therapy highlighting clinical trials with the best results, mechanisms of resistance, combination therapies and future
directions in this interesting field. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | International Journal of Tumor Therapy | en_US |
| dc.subject | Immunotherapy, Immune checkpoint molecules, Monoclonal antibodies | en_US |
| dc.title | Immune Checkpoint Blockade Therapy for Cancer | en_US |
| dc.type | Article | en_US |
